Fetal growth retriction (FGR) is a serious obstetric complication affecting up to 24,000 Australian pregnancies each year. FGR is most often caused by placental dysfunction, resulting in oxygen and nutrient deficiencies, and a fetus that fails to thrive. Low levels of oxygen in the fetus' blood produces a state of 'oxidative stress'. The developing brain is especially vulnerable to oxidative stress, with fetal growth restriction contributing to high rates of morbidity and mortality in these infants, including cerebral palsy. The aim of this research is to assess the impact of maternal antenatal melatonin supplementation on early childhood neurodevelopmental outcomes caused by FGR.
|Effective start/end date||1/07/18 → 31/12/20|